Recombinant Proteins Market (2026 - 2033)

Recombinant Proteins Market Summary

The global recombinant proteins market size was estimated at USD 3.4 billion in 2025 and is projected to grow from USD 3.9 billion in 2026 to USD 6.6 billion by 2033, growing at a CAGR of 8.0% from 2026 to 2033. The North America recombinant proteins market held the largest share of 41.4% of the global market in 2025. The rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is anticipated to drive market growth.

Furthermore, the rising preference for biopharmaceuticals, such as monoclonal antibodies, vaccines, and therapeutic enzymes, are other factors contributing to the growth of the market for recombinant proteins. The advantages offered by recombinant proteins drive the increasing preference for research over natural proteins. For instance, recombinant proteins can be synthesized with a high protein yield, no animal contaminants, and controlled batch-to-batch variation.

Moreover, the amino acid sequences of these proteins can be easily altered, and unnatural amino acids can be incorporated as required. Commonly used recombinant proteins for research applications include growth factors family proteins, such as fibroblast growth factors, vascular endothelial growth factors, and neurotrophins. Similarly, cytokines, such as interferons, chemokines, interleukins, & pro-inflammatory cytokines, and enzymes, such as recombinant proteases, kinases, & nucleases, are used for life sciences research that requires biologically active proteins.

Moreover, as per Global Genes, more than 400 million people around the globe are living with rare genetic diseases. This number explains the dire need for treatments, the betterment of clinical settings, and health awareness. Advanced research and knowledge of drug-targeting mechanisms are crucial tools for medicine development. Many regions have developed biobanks from cohort programs to provide researchers with high-quality samples for revolutionizing treatment efforts. This can result in an increased focus on discovering biomarkers for various conditions. For instance, in September 2024, the U.S. Food and Drug Administration (FDA) granted approval for isatuximab-irfc (Sarclisa), developed by Sanofi-Aventis U.S. LLC, to be used in combination with bortezomib, lenalidomide, and dexamethasone. This treatment is specifically indicated for adults diagnosed with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplantation.

Key market players in the recombinant proteins marketspace are investing in their R&D programs to increase research productivity and grow their offerings for revenue generation. For instance, in 2023, Merck & Co. significantly increased its investment in research and development, allocating over USD 30 billion. This is more than twice the company's R&D expenditure of USD13.5 billion in 2022. Such instances are expected to support the growth of R&D activities further and demonstrate the vision of companies to deliver a difference to patients. Such initiatives by companies will likely supplement the market growth in the coming years.

The COVID-19 pandemic fueled the research and development race to find treatments and diagnostic tools for the SARS-CoV2 virus. Recombinant technology played a major role during the initial phase, resulting in many recombinant proteins-based COVID-19 vaccines entering the market with emergency use approval. For instance, in December 2021, WHO issued a 9^th COVID-19 vaccine for emergency use listing (EUL). This EUL allowed vaccination access in low and middle-income countries such as Turkey, Colombia, Argentina, Mexico, Poland, South Africa, Iran, Ukraine, and others. Similarly, in June 2022, The Drugs Controller General of India (DCGI) approved the Covovax vaccine from the Serum Institute of India (SII) for children aged 7 to 12 years, a recombinant protein-based vaccine.

Intense efforts are being taken by multiple players for therapeutics via accelerated cycles of innovation to bring breakthroughs to patients faster. Furthermore, the demand for effective, efficient, and safe drugs enhanced the popularity of biopharmaceuticals. Moreover, the need for developing a COVID-19 vaccine on a large scale in minimal time, along with its continuous commercial manufacturing activities, had a positive impact and encouraged biologics-based research activities and eventually supported the recombinant proteins market growth.

Market Dynamics

The recombinant proteins market is experiencing steady growth due to the increasing use of recombinant proteins in biopharmaceutical production, drug discovery, vaccine development, diagnostics, and cell & gene therapy research. Rising demand for biologics, growing investments in biotechnology and life sciences research, and advancements in protein expression and purification technologies are supporting market expansion. In addition, the increasing prevalence of chronic and infectious diseases, along with expanding applications in personalized medicine and regenerative therapies, is expected to further drive the growth of the recombinant proteins market.

Market Concentration & Characteristics

The recombinant proteins industry is witnessing significant innovation driven by advancements in protein engineering, expression systems, and bioprocessing technologies. Companies are increasingly adopting next-generation mammalian, microbial, and cell-free expression platforms to improve protein yield, stability, scalability, and overall production efficiency. These technological advancements are also helping reduce production timelines and support cost-effective manufacturing processes. In addition, the integration of AI-enabled protein design, automation, and continuous bioprocessing technologies is further enhancing manufacturing precision and operational efficiency. The growing use of advanced production platforms is supporting the development of high-quality recombinant proteins for therapeutics, vaccines, diagnostics, and research applications, thereby contributing to overall market growth.

The recombinant proteins industry is witnessing moderate to high M&A activity, driven by the increasing demand for biologics, biosimilars, and advanced therapeutic proteins. Leading biotechnology and pharmaceutical companies are actively pursuing acquisitions, partnerships, and strategic collaborations to strengthen their recombinant protein portfolios, expand manufacturing capabilities, and accelerate innovation in protein therapeutics. This consolidation trend is enabling companies to enhance their technological expertise in expression systems, purification technologies, and large-scale bioproduction. For instance, in April 2024, HTL Biotechnology acquired Modern Meadow’s recombinant protein platform, including human recombinant collagen type III, to strengthen its capabilities in biomedical, cosmetic, and regenerative medicine applications.

Regulatory frameworks play a critical role in shaping the recombinant proteins industry by establishing stringent standards for product safety, efficacy, quality control, and manufacturing consistency. Compliance with Good Manufacturing Practices (GMP), biologics regulations, and international quality standards is essential for the development and commercialization of recombinant protein therapeutics, vaccines, and research-grade proteins. These regulations govern protein expression, purification, validation, and batch reproducibility, particularly in biopharmaceutical and clinical applications. Although regulatory compliance increases production costs and extends approval timelines, it enhances product reliability, patient safety, and market credibility, thereby supporting long-term market growth.

Product expansion in the recombinant proteins industry is being driven by the increasing demand for high-purity, application-specific proteins across therapeutics, diagnostics, vaccine development, and cell & gene therapy research. Market players are continuously broadening their portfolios with advanced recombinant cytokines, growth factors, enzymes, antibodies, and custom protein expression solutions to improve research efficiency and therapeutic outcomes. Companies are also focusing on technologically advanced expression platforms and scalable production systems to enhance protein yield, stability, and reproducibility. Overall, continuous innovation and portfolio expansion are strengthening product accessibility and supporting the growing adoption of recombinant proteins in biopharmaceutical and life sciences applications. For instance, in January 2025, Bio-Techne Corporation expanded its R&D Systems designer protein portfolio with AI-engineered recombinant proteins to enhance cell therapy, regenerative medicine, stem cell research, and immune cell expansion applications.

Regional expansion in the recombinant proteins industry is being driven by the growing biopharmaceutical industry and increasing demand for biologics, vaccines, and cell & gene therapies across emerging and developed regions. Companies are strengthening their presence in Asia-Pacific, Latin America, and the Middle East & Africa through strategic collaborations, distribution partnerships, and investments in local manufacturing facilities. In addition, rising investments in biotechnology research, expanding bioprocessing infrastructure, and growing healthcare expenditure are supporting the accessibility and adoption of recombinant protein products globally.

Case Study: Protalix BioTherapeutics’ Plant-Based Recombinant Protein Platform

Overview

Protalix BioTherapeutics has developed recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. This innovative platform enables the production of complex recombinant proteins in plant cells, offering an alternative to traditional mammalian and microbial expression systems. In 2024, the company reported record revenues, driven by increased commercialization of its recombinant protein therapeutics and continued advancement of its pipeline candidate PRX-115, a recombinant therapy targeting gout.

Market Relevance

The case highlights the growing shift toward alternative, cost-efficient, and scalable expression technologies within the recombinant proteins market. Plant-based systems are gaining traction for their ability to reduce production costs, improve scalability, and minimize contamination risks compared to conventional systems. This approach is particularly relevant for rare diseases and metabolic disorder therapeutics, where demand for biologics is steadily increasing.

Key Outcomes

• Demonstrated successful commercial scalability of plant-based recombinant protein production

• Supported rising demand for recombinant therapeutics in rare and metabolic diseases

• Strengthened innovation in non-mammalian expression systems, enhancing production flexibility and cost efficiency

Analyst Perspective

The recombinant proteins market sits at the core of modern biologics manufacturing, underpinned by structural demand drivers that few life sciences segments can rival, the sustained expansion of monoclonal antibody pipelines, the growing reliance on cytokine- and growth factor-based therapies in oncology and immunology, and the accelerating adoption of protein-based modalities in cell and gene therapy workflows. What increasingly defines competitive advantage in this space is not isolated protein categories, but the ability to integrate end-to-end expression platforms, scalable upstream production systems, and high-fidelity purification technologies that reduce batch variability while supporting rapid clinical-to-commercial transitions. Over time, value is expected to concentrate among players capable of pairing broad recombinant protein portfolios with platform-based manufacturing ecosystems, enabling biopharma customers to compress development timelines, ensure regulatory consistency, and support personalized and next-generation therapeutic formats at industrial scale.

Product Insights

The cytokines & growth factors segment held the largest share of 24.8% in 2025 and is expected to grow strongly over the forecast period, driven by its wide applications in cancer, HIV/AIDS, immunology, and neuroscience research. This segment is anticipated to grow exponentially throughout the forecast period. This is a result of its extensive use in the fields of cancer, HIV/AIDS, COVID-19, immunology, and neuroscience, among others. Furthermore, growth factors and cytokines play a significant role in cancer research. Studies regarding the use of growth factors in cancer treatment have improved understanding and given rise to new goals for chemotherapy. Additionally, the need for recombinant protein products in regenerative medicine and rising financing for research & development in the fight against cancer are driving up demand globally.

The antibodies segment is expected to witness significant growth during the forecast period. Recombinant antibodies are extensively used in diagnostic assays, including ELISA, western blotting, and immunohistochemistry. Their high specificity and sensitivity make them ideal for detecting biomarkers and disease-related antigens. This has driven their demand for diagnostic applications, particularly for diseases like cancer, infections, and autoimmune disorders.

Application Insights

The therapeutics segment dominated the global market, accounting for 34.2% in 2025, driven by the rising demand for protein-based treatments across a wide range of diseases. The demand for protein-based treatment is anticipated to rise as the prevalence of diseases such as metabolic disorders, cancer, genetic disorders, and immune diseases rises. Additionally, cancer is one of the leading causes of mortality globally, and the World Health Organization (WHO) predicts a large rise in cancer cases in the coming years. As a result, it is projected that the market for therapeutics will experience growth.

The drug discovery & development segment is anticipated to grow significantly during the forecast period. Protein therapeutics offer highly effective treatments for illnesses like diabetes, cancer, infectious disorders, hemophilia, and anemia. As per the International Diabetes Federation, there will be 643 million diabetics worldwide by 2030 and 783 million by 2045. With such growth in the diabetic population, the demand for the development of effective recombinant proteins is likely to show growth in the coming years.

End Use Insights

The pharmaceutical & biotechnology companies segment led the market, accounting for 38.6% of revenue in 2025, driven by rising investment in protein-based drug development for chronic and infectious diseases. The inclination towards biologics and biosimilars has resulted in a cascade of multi-million investments by bio-manufacturers in R&D to grow the pipeline of products, devise new technologies, and advance bioprocessing tools. The increasing market demand, rising competition among players, and various applications by end users have also contributed to advancements in recombinant protein products.

The academic & research institutes segment is expected to grow significantly over the forecast period. The R&D sector also witnessed increased investments in terms of collaboration & partnerships between academia and industries. For example, Pfizer’s Center for Therapeutic Innovation (CTI) is a platform for collaboration within the healthcare ecosystem. CTI actively collaborates with academic institutes and investigators to tackle the challenges using Pfizer’s concepts. Collaborations like these fuel drug development research and potential therapies for patients, eventually propelling market growth.

Host Cell Insights

The mammalian segment held the largest share of 42.1% in 2025, driven by its high suitability for producing complex, functionally active proteins with proper folding and post-translational modifications. Mammalian protein expression is becoming increasingly in demand as the market for proteomics & biologics expands. Since they are provided easily, protein expression systems are simple to include in high throughput systems for effective biologics and proteomics investigations.Moreover, the focus on producing biopharmaceutical goods has increased due to factors such as the rising incidence and prevalence of cancer and rising research and development (R&D) efforts, which drive the market's expansion.

The bacterial cells segment is expected to show a lucrative growth rate from 2026 to 2033. The use of bacterial cells as host cells in biotechnology and research has significantly increased. Bacterial cells, mainly Escherichia coli (E. coli), are favorable for protein expression due to their rapid growth, well-characterized genetics, and ease of handling. The growing demand for a wide range of applications, such as drug development and antibodies, is anticipated to propel the growth of bacterial cells over the forecast period.

Regional Insights

The North America recombinant proteins market dominated the global market, accounting for 41.4% of revenue in 2025, driven by rising research spending, robust healthcare infrastructure, and several significant market players. In addition, recombinant proteins are one of the tested treatments for such disorders, therefore, the chronic diseases spreading throughout the region are producing a big demand for recombinant protein therapies.

U.S. Recombinant Proteins Market Trends

Recombinant proteins market in the U.S. has emerged as a growing and dynamic sector within the life sciences industry. This growth can be attributed to the expansion of biotechnology, which creates the demand for highly purified and well-characterized proteins for research purposes. The market is further fueled by the pharmaceutical & biopharmaceutical sectors, where protein-based therapies and drug development continue to gain prominence.

Europe Recombinant Proteins Market Trends

The Europe recombinant proteins market held a substantial share in 2025, driven by stringent regulatory standards ensuring high-quality biologics and protein-based therapeutics. Recombinant proteins are fundamental in research, fueling their demand in Europe.

The UK recombinant proteins market held a significant share in 2025. Key industry players invest strategically in the UK to capitalize on the expanding biopharmaceutical domain. For instance, in March 2023, the UK government announced plans to allocate USD 295.35 million (£277 million) to support manufacturing projects in medical diagnostics & human medicines of four life sciences companies in the UK. This funding is a combination of government support & private investment aimed at enhancing the manufacturing & innovation capabilities of the UK life sciences sector. These developments are expected to drive market growth within the UK.

Germany recombinant proteins market is anticipated to grow significantly over the forecast period. The growing collaboration among organizations to enhance research studies in Germany propels recombinant proteins market growth.

Asia Pacific Recombinant Proteins Market Trends

The Asia Pacific recombinant proteins market is expected to register the fastest CAGR of 9.6% over the forecast period, driven by rising investments in the healthcare and biotechnology sectors. In addition, developing advanced techniques in proteomic and genomic research propels the market growth in Asia Pacific.

The recombinant proteins market in China is anticipated to witness exponential growth over the forecast period. This can be attributed to the rising investments in stem cell and cancer research from government & private organizations. These investments help develop infrastructure for academic and research institutes by using the latest technologies.

Japan recombinant proteins market is the largest market in Asia Pacific region and it is expected to exhibit high growth over the forecast period. Increasing clinical research studies and collaborative strategic initiatives are anticipated to propel market growth in Japan.

MEA Recombinant Proteins Market Trends

Middle East and African countries have a very low global market share due to a lack of awareness, infrastructure, and skilled personnel in these regions. Saudi Arabia’s market is anticipated to grow significantly over the forecast period owing to increasing awareness and ongoing economic development.

Saudi Arabia's Recombinant proteins market is expected to grow over the forecast period. The growth of Saudi Arabia's market can primarily be attributed to various initiatives undertaken by the government to expand the biotechnology sector in the country.

The Recombinant proteins market in UAE is anticipated to grow moderately over the forecast period. Rising investments by academic & research institutes to perform biopharmaceutical research are expected to boost the regional market in the coming years.

Key Recombinant Proteins Company Insights

Key players in the recombinant proteins market are implementing various strategies, including partnerships through mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence.

Key Recombinant Proteins Companies:

The following key companies have been profiled for this study on the recombinant proteins market. 

• Sino Biological, Inc.

• Bio-Techne

• GenScript

• Bio-Rad Laboratories, Inc.

• Merck KGaA

• Thermo Fisher Scientific

• Proteintech Group, Inc.

• Enzo Life Sciences, Inc.

• Abnova Corporation

• RayBiotech Life Inc.

• STEMCELL Technologies Inc.

Competitive Benchmarking

Recent Development

• In September 2024, ScaleReady and Bio-Techne Corporation announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high-efficiency closed system cell and gene-modified cell therapy manufacturing.

• In March 2024, Proteintech, announced the opening of its new state-of-the-art facility, including laboratory and office space in the UK. The new building houses research and development, production, logistics, and administration in an area more than three times larger than its previous space.

• In August 2023, Danaher Corporation announced that it had signed a definitive contract to acquire Abcam Plc. Under the terms of the agreement, Danaher will acquire all of Abcam's outstanding shares for USD 24.00 per share in cash, for a total company value of approximately USD 5.7 billion, including assumed indebtedness along with net of acquired cash.

• In January 2023, Thermo Fisher Scientific Inc. completed the acquisition of PeproTech. PeproTech will provide a strategic fit for the company’s biosciences business, allowing it to better serve pharma and biotech customers by adding new capabilities to its existing portfolio.

Recombinant Proteins Market Report Scope

Global Recombinant Proteins Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the recombinant proteins market based on product, application, end use, host cell, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Cytokines & Growth Factors

    • Interferons (IFNs)

    • Interleukins (ILs)

    • Others

  • Antibodies

  • Immune checkpoint proteins

  • Virus Antigens

  • Enzymes

    • Kinases

    • Metabolic enzymes

    • Others

  • Recombinant Regulatory Protein

  • Hormones

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug Discovery & Development

  • Therapeutics

    • Biologics

    • Vaccines

    • Cell & Gene Therapies

    • Others

  • Research

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharma & Biotechnology Companies

  • Academic & Research Institutes

  • Diagnostic Laboratories

  • Others

• Host Cell Outlook (Revenue, USD Million, 2021 - 2033)

  • Mammalian systems

  • Insect Cells

  • Yeast & Fungi

  • Bacterial Cells

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations